-
Mashup Score: 9PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues - 7 month(s) ago
Metastatic prostate cancer, Castration-resistant prostate cancer, PARP inhibitor, Androgen receptor signalling inhibitor
Source: European UrologyCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues - 7 month(s) ago
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues
Source: European UrologyCategories: Latest Headlines, UrologyTweet-
Lest I ask you to rely on my opinion, I wanted to close today’s email with a brilliant commentary/editorial from many of the big names in advanced prostate cancer. This short article is a quick but brilliant read so I encourage any of you who treat advanced prostate cancer to take the time to go through these authors summary of the data.
-
-
Mashup Score: 1
Men at a high genetic risk adhering to a healthy lifestyle had a reduced risk of lethal prostate cancer compared with men at a high genetic risk not adhering to a healthy lifestyle. The genetic risk of prostate cancer may be modifiable.
Source: European UrologyCategories: General Medicine News, Latest HeadlinesTweet-
RT @EUplatinum: Current Issue: A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer https://t.co/8YIr48YlGu @a_plym…
-
-
Mashup Score: 0Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification - 1 year(s) ago
We present the rationale for keeping the “cancer” label for grade group 1 (GG1) prostate cancer. Maintaining GG1 as the lowest grade outweighs the potential benefits that a benign designation may bring. Patient and surgeon education on the vital role of active surveillance for GG1 cancers and avoidance of overtreatment should be the focus rather than such a drastic change in nomenclature.
Source: European UrologyCategories: Latest Headlines, UrologyTweet-
Highlight: Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification https://t.co/6J00EBpXuT @DrNetto @DrMahul @evacomperat @CaDxPath @GUpathMenon @ro36693000 @MarkARubin1 @IanCreeUK @daniel_berne https://t.co/ozjcnzuB0g
-
-
Mashup Score: 2Obturator Nerve Injury in Robotic Pelvic Surgery: Scenarios and Management Strategies - 1 year(s) ago
The obturator nerve can be damaged during urological or gynecological surgeries. Obturator nerve injury is a preventable complication for which there are different management options, depending on the type of nerve injury.
Source: European UrologyCategories: Latest Headlines, UrologyTweet-
Surgery in Motion: Obturator Nerve Injury in Robotic Pelvic Surgery: Scenarios and Management Strategies https://t.co/UfMii3AX9C @aniballariva @arefsayeghs @DoctorSotelo @Cacciamani_MD @JaimePoncel @LGMedinaN @badamic14 https://t.co/ZLnFkMcX3A
-
-
Mashup Score: 3Climate-smart Actions in the Operating Theatre for Improving Sustainability Practices: A Systematic Review - 1 year(s) ago
Climate-smart actions in the operating room (OR) are urgently needed and deserve more awareness and implementation. Although some actions are mainly the role of stakeholders, many of them are within reach and should be applied immediately by the healthcare providers working in the OR. More educational programmes should be implemented for healthcare workers as well as those in training. Reducing…
Source: European UrologyCategories: Latest Headlines, UrologyTweet-
Highlight: Climate-smart Actions in the Operating Theatre for Improving Sustainability Practices: A Systematic Review https://t.co/lOtVtKaX1U @BenjaminPradere @MalletR @delataillealex @BladouFranck @bardet_florian @pr_gfournier @xaviermatillon @MejeanArnaud @VMisra @ugopinar https://t.co/g1EE99yScb
-
-
Mashup Score: 1
Repeated, prostate-specific antigen–based screening with a 4-yr interval in men aged 55–69 yr reduces prostate cancer–specific mortality and metastatic prostate cancer after a median follow-up of 21 yr. Additionally, coinciding overdiagnosis is lower than previously suggested.
Source: European UrologyCategories: Hem/Oncs, Latest HeadlinesTweet-
A Detailed Evaluation of the Effect of Prostate-specific Antigen–based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for ProstateCa-European Urology https://t.co/wSnoCEaTst
-
-
Mashup Score: 0Urology for Social Responsibility: Choosing a Lane - 1 year(s) ago
Passion. Purpose. Peace. Urologists like to P.
Source: European UrologyCategories: Latest Headlines, UrologyTweet-
Articles in Press: Urology for Social Responsibility: Choosing a Lane https://t.co/o1Gl8Hne96 @endourologyucsd https://t.co/JZv62ARIwE
-
-
Mashup Score: 2Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer - 1 year(s) ago
In this clinical trial, we investigated a novel noninvasive treatment option of stereotactic radiation therapy for the treatment of primary kidney cancer. We found that stereotactic radiation was safe and effective for the treatment of primary kidney cancers.
Source: European UrologyCategories: Latest Headlines, UrologyTweet-
Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer https://t.co/nD0yQWtsUr - Radiographic LC at 1 yr was observed in 94% of patients - Median pretreatment growth rate: 0.8 cm/yr; median post-treatment growth rate: 0.0 cm/yr https://t.co/jlvrBZ5sa0
-
-
Mashup Score: 5Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial - 1 year(s) ago
In patients with oligometastatic renal cell carcinoma, radiotherapy to all metastases followed by short-course pembrolizumab is safe, with a grade 3 adverse event rate of 13%. The combination is effective, with median progression-free survival of 15.6 mo and 2-yr local control of 92%.
Source: European UrologyCategories: General Medicine News, Latest HeadlinesTweet-
RT @EUplatinum: @_ShankarSiva @declangmurphy @PeterMacCC Read the article here: https://t.co/WB7RKUfaYK
-
Lest I ask you to rely on my opinion, I wanted to close today’s email with a brilliant commentary/editorial from many of the big names in advanced prostate cancer. This short article is a quick but brilliant read so I encourage any of you who treat advanced prostate cancer to take the time to go through these authors summary of the data.